1.
Gershony G, Furman M, Davis E, Weintraub W, King
S. Predictors of Restenosis after Angioplasty in Chronic
Total Coronary Occlusion. Circulation 74:I-282, 1986.
2.
Furman MI, Kaplan DT, Ryan SM, Lipsitz LA, Goldberger
AL. A Nonlinear Parameter Measures Loss of Complexity in
Heart Rate Time Series Data with Aging. Clin Res. 1990.
3.
*Furman MI, Dise KR, Bray PF, Goldschmidt-Clermont
PJ. Thrombin Activation of the Fibrinogen Receptor Requires
Tyrosine Phosphorylation of Platelet Proteins. Circulation
86:I-303, 1992.
4.
*Furman MI, Faraday N, Dise KR, Rosenfeld BA, Goldschmidt-Clermont
PJ. In vivo Platelet Protein Tyrosine Kinase Activity as
a Marker for Hyper-Aggregable Platelets. Circulation 88;I-458,
1993.
5.
Michelson AD, Benoit SE, Furman MI, Barnard MR, Nurden
PN, Nurden AT. Reversible Cytoskeletal-Mediated Redistribution
of Platelet Surface GPV. Blood 86:454a, 1995.
6.
*Furman MI, Becker RC, Yarzbeski J, Savageau J, Gore
JM, Goldberg RJ. Leukocytosis and Increased Mortality Following
Acute Myocardial Infarction: A Multi-Hospital, Community-Wide
Perspective. Circulation 92:I-664, 1995.
7.
*Furman MI, Benoit SE, Becker RC, Borbone M. Weiner
BH, Michelson AD. Thrombin Receptor-Mediated Platelet Reactivity
is increased in Stable Coronary Artery Disease, Circulation
92:I-343, 1995.
8.
Liu L, Furman M, Zhang O, Spencer F, Michelson A,
Gore J, Becker R. Fibrinogen Inhibits Platelet Activation
by a-Thrombin and Trap. Blood 88 (Suppl B): 48b, 1996
9.
Liu L, Furman M, Zhang O, Spencer F, Michelson A,
Gore J, Becker R. Clot Bound Thrombin Activates Platelets
as Potent as Fluid Phase Thrombin. Blood 88 (Suppl B): 48b,
1996.
10.
Liu L, Zhang O, Spencer F, Chung E, Furman M, Gore
J, Becker R. Persistent Survival of Platelet Factor Va Activity
in Plasma. Blood 88 :526a, 1996.
11.
*Furman MI, Liu L, Benoit SE, Becker RC, Barnard
M, Michelson AD. The Cleaved Peptide of the Thrombin Receptor
is a Strong Platelet Agonist. Circulation 94: I-580, 1996.
12.
*Furman MI, Benoit SE, Borbone M, Becker RC, Michelson
AD. Monocyte-Platelet Aggregation Is Increased In Stable
Coronary Artery Disease. Circulation 94: I-811, 1996
13.
Grabowski EF, Boor SE, Laposata M, Johnson SM, Furman
MI, Benoit SE, Michelson AD. Platelet Hyperaggregability
and Aspirin Resistance In Two Brothers With Syndrome X:
Non-Cycloxygenase-Dependent Platelet Defect. Thromb Haemost
77:71, 1997
14.
*Furman MI, Benoit SE, Borbone M, Becker RC, Michelson
AD. Patients With Stable Coronary Artery Disease Have Increased
Platelet Reactivity And Increased Circulating Monocyte-Platelet
Aggregates. Thromb Haemost: 77:62, 1997.
15.
*Furman MI, Nurden P, Berndt MC, Nurden AT, Benoit
SE, Liu L, Rohrer MR, Barnard MR, and Michelson, AD. The
Cleaved Peptide of PAR1 Results in a Redistribution of Platelet
Surface GPIb to the Surface-Connected Canalicular System.
Circulation: 98, I-523, 1998
16.
Bray PF, Furman MI, Coleman L, Hamlington J, Goldschmidt-Clermont
P, Hendrix C, Mascelli MA, Barnard M, Kickler T, Christie
D, Kundu S, and Michelson AD. Integrin b3 (GPIIIa) PlA polymorphisms
on platelets display different sensitivity to agonists and
antagonists. Blood 92:28a, 1998.
17.
*Furman MI, Shilale EA, Barnard MR, Alugupalli K,
Rohrer MJ, and Michelson AD. Circulating monocyte-platelet
aggregates are a marker of acute myocardial infarction in
patients presenting to the emergency room with chest pain.
Blood 92:188a, 1998.
18.
Claytor RB, Li J-M, Rohrer MJ, Frelinger AL, Garnette CSC,
Barnard MR, Krueger LA, Furman MI, and Michelson
AD. Prolonged exposure of platelets to thrombin decreases
platelet-endothelial cell adhesion. (Presented at the 10th
Annual Meeting of the Society for Vascular Medicine and
Biology, Washington, DC, June 4 - 5, 1999.)
19.
Claytor B, Li J-M, Furman MI, Garnette CSC, Rohrer
MJ, Barnard MR, Krueger L, Frelinger AL, and Michelson AD.
Laser scanning cytometry: a novel method for the detection
of platelet-endothelial cell adhesion. Thrombosis and Haemostasis
82:527, 1999 (Presented at the XVIIth Congress of the International
Society on Thrombosis and Haemostasis, Washington, D.C.,
August 19, 1999.)
20.
Kereiakes D, Mueller M, Sane D, Braden GA, Kottke-Marchant
K, Topol EJ, Furman MI, and Michelson AD. Use of
the Ultegra-rapid platelet function assay to assess the
degree of platelet inhibition in patients treated with abciximab.
Results of a multicenter study. Thrombosis and Haemostasis
82:646-647 1999. (Presented at the XVIIth Congress of the
International Society on Thrombosis and Haemostasis, Washington,
D.C., August 19, 1999.)
21.
Sane D, Braden GA, Kereiakes D, Mueller M, Topol E, Kottke-Marchant
K, Furman MI, and Michelson AD. Rapid bedside measurement
of platelet aggregation in patients undergoing percutaneous
coronary intervention and treated with abciximab. Results
of a multi-center study of Accumetrics Ultegra-rapid platelet
function assay. (Presented at the European Society of Cardiology,
Barcelona, Spain, August 28 - September 1, 1999.)
22.
Claytor RB, Michelson AD, Li J-M, Frelinger AL, Rohrer MJ,
Garnette CSC, Barnard MR, Krueger L, and Furman MI.
The cleaved peptide of PAR1 is a more potent stimulant of
platelet-endothelial cell adhesion than thrombin. (Presented
at the 85th Clinical Congress of the American College of
Surgeons, San Francisco, October 10 - 15, 1999.)
23.
*Furman MI, Yarzebski J, Lessard D, Gore JM, and
Goldberg RJ. 22 Year (1975-97) trends in the incidence,
in-hospital and 2 year mortality rates from initial non
Q-wave myocardial infarction: A community-wide perspective.
Circulation 100:I-103, 1999.
24.
Kereiakes D, Mueller M, Sane D, Braden GA, Kottke-Merchant
K, Furman MI, and Michelson AD. Use of the Ultegra-rapid
platelet function assay to assess the degree of platelet
inhibition in patients treated with abciximab. Results of
a multicenter study. Circulation 100:I-152, 1999.
25.
Sane D, Braden GA, Furman MI, Michelson AD, Mueller
M, Kottke-Merchant K and Steinhubel, SR. Ultegra rapid platelet
function assay (U-RPFA) correlates with the degree of abciximab
platelet inhibition measured by receptor occupancy: Results
of a multicenter study. Circulation 100:I-153, 1999.
26.
Dauerman HL,Yarzebski J, Lessard D, Furman MI, Gore
JM, and Goldberg RJ. Ten year trends in the incidence, outcome,
and reperfusion strategies for Q wave myocardial infarction.
Circulation 100:I-359, 1999.
27.
Garnette CSC, Rohrer MJ, Valeri CR, Barnard MR, Frelinger
AL,Claytor RB, Krueger LA, Hechtman HB, Furman MI,
and Michelson AD. Cathepsin G proteolyses platelet surface
P-selectin and disaggregates leukocyte-platelet aggregates:
mechanism for the loss of surface P-selectin from circulating
degranulated platelets. Circulation 100:I-610, 1999.
28.
*Furman MI, Krueger LA, Frelinger AL, Barnard MR,
Mascelli MA, Nakada MT, and Michelson AD. GPIIb-IIIa antagonist-induced
reduction in platelet procoagulant activity in whole blood:
Augmentation by thrombin inhibitors. Circulation 100:I-681,
1999.
29.
*Furman MI, Krueger LA, Frelinger AL, Barnard MR,
Mascelli MA, Nakada MT, and Michelson AD. Tirofiban and
eptifibatide, but not abciximab, induce leukocyte-platelet
aggregation. Circulation 100:I-681, 1999.
30.
Steinhubel, SR, Kottke-Merchant K, Furman MI, Michelson
AD, Keriakes DJ, Sane D, and Braden GA. Rapid bedside measurement
of platelet aggregation in patients undergoing PCI and treated
with Abciximab: Results of a multi-center study of the Ultegra
rapid platelet function assay (U-RPFA). Circulation 100:I-856,
1999.
31.
Frelinger AL, Furman MI, Krueger LA, Barnard MR,
and Michelson AD. Dissociation of GPIIb-IIIa antagonists
from platelets does not result in fibrinogen binding or
platelet aggregation. Blood 94:21a, 1999. (Presented at
the 41st Annual Meeting of the American Society of Hematology,
New Orleans, December 3 - 7, 1999.)
32.
Bray PF, Michelson AD, Furman MI, Salmon J, Bolton
E, Afshar-Kharghan V, and Lopez JA. Correlating genetic
variations in adhesive receptors with platelet function.
Blood 94:216a, 1999. (Presented at the 41st Annual Meeting
of the American Society of Hematology, New Orleans, December
3 - 7, 1999.)
33.
Krueger LA, Michelson AD, Frelinger AL, Barnard MR, Mascelli
MA, Nakada MT, and Furman MI. Leukocyte-platelet
aggregation is augmented by GPIIb-IIIa antagonists tirofiban,
eptifibatide and RGDS but not abciximab. (Accepted for presentation
at the XXth International Congress of the International
Society for Analytical Cytology (ISAC), Montpellier, France,
May 20 - 25, 2000.)
34.
Krueger LA, Michelson AD, Frelinger AL, Barnard MR, Mascelli
MA, Nakada MT, and Furman MI. Platelet procoagulant
activity is diminished by GPIIb-IIIa antagonists in whole
blood and is further diminished by thrombin inhibitors.
(Accepted for presentation at the XXth International Congress
of the International Society for Analytical Cytology (ISAC),
Montpellier, France, May 20 - 25, 2000.)
35.
*Furman MI, Krueger, LA Barnard MR, and Michelson
AD. Circulating monocyte-platelet aggregates are a more
sensitive marker of platelet activation than P-selectin-positive
platelets. Circulation 102: II-776, 2000.(Accepted for oral
presentation at the 73rd Scientific Sessions of the American
Heart Association, New Orleans, LA, November 12 - 15, 2000.)
36.
*Furman MI, Barnard MR, Krueger LA, Fox ML, Lessard
DM, Marchese P, Goldberg RJ, and Michelson AD. Circulating
monocyte-platelet aggregates are an early marker of acute
myocardial infarction. Circulation 102: II-498, 2000 (Accepted
for oral presentation at the 73rd Scientific Sessions of
the American Heart Association, New Orleans, LA, November
12 - 15, 2000.)
37.
Frelinger AL, Mattson JC, Furman MI, Barnard MR,
Krueger LA, Marchese PJ, Farrah D, OšNeill WW, and Michelson
AD. Monitoring tirofiban therapy in patients: effect of
ex vivo anticoagulant. Thrombosis and Haemostasis Supplement
July 2001 (abstract P377). (Presented at the XVIIIth Congress
of the International Society on Thrombosis and Haemostasis,
Paris, France, July 8, 2001.)
38.
*Furman MI, Michelson AD, Krueger LA, Mueller MN,
Broderick TM, Schneider J, Howard W, Fox MR, Barnard MR,
Frelinger AL, and Kereiakes DJ. Effects of _ dose abciximab
in the presence of either dalteparin or heparin on platelet
inhibition, as determined by 3 independent assays. Thrombosis
and Haemostasis Supplement July 2001 (abstract P382). (Presented
at the XVIIIth Congress of the International Society on
Thrombosis and Haemostasis, Paris, France, July 8, 2001.)
39.
Michelson AD, Barnard MR, Krueger LA, Valeri CR, Furman
MI. Circulating monocyte-platelet aggregates are a more
sensitive marker of platelet activation than platelet surface
P-selectin. Thrombosis and Haemostasis Supplement July 2001
(abstract OC2494). (Presented at the XVIIIth Congress of
the International Society on Thrombosis and Haemostasis,
Paris, France, July 11, 2001.)
40.
Rohrer MJ, Claytor RB, Garnette CSC, Powell CC, Barnard
MR, Furman MI, and Michelson AD. Platelet-monocyte
aggregates in patients with chronic venous insufficiency
remain elevated following correction of the reflux. Cardiovascular
Surgery 9 (suppl 2):25-26, 2001. (Presented at the 25th
World Congress of the International Society for Cardiovascular
Surgery, Cancun, Mexico, September 9 - 13, 2001.)
41.
*Furman MI, Davidson MC, Anderson FA, Budaj A, Goodman
SG, Avezum A, Lopez-Sendon J, Klein W, and Gore JM. Relationship
between elevated leukocyte count and hospital clinical events
in patients with acute coronary syndromes: Findings from
the global registry of coronary events. (Accepted for oral
presentation at the 74rd Scientific Sessions of the American
Heart Association, Anaheim, CA, November 11 - 14, 2001).
42.
Kereiakes D, Michelson A, Krueger L, Mueller M, Broderick
T, Schneider J, Howard W, Fox M, Barnard M, Furman M.
Randomized comparison of dalteparin vs. unfractionated heparin
in combination with abciximab during percutaneous coronary
intervention: effects on leukocyte-platelet aggregation,
platelet activation and GP IIb/IIIa receptor expression.
Circulation 104:II-38, 2001. (Presented at the 74th Scientific
Sessions of the American Heart Association, Annaheim, November
12, 2001.)
43.
Frelinger AL, Barnard MR, Furman MI, Krueger LA,
Michelson AD. Combined effects of mild hypothermia and GPIIb-IIIa
antagonists on platelet-platelet and leukocyte-platelet
aggregation. Circulation 104:II-706 - II-707, 2001. (Presented
at the 74th Scientific Sessions of the American Heart Association,
Anaheim, November 14, 2001.)
44.
Krueger LA, Furman MI, Barnard MR, Marchese PJ, Frelinger
AL and Michelson AD, Augmentation of Platelet Activation
in the Presence of GPIIb-IIIa Receptor Antagonists may be
the Result of Murine Monoclonal Antibody-Mediated Platelet
Surface FcgRIIa Receptor Activation. Cytometry, Supplement
11, 2002. Presented at the XXI Congress of the International
Society of Analytical Cytology, San Diego, CA, May 4-9,
2002
45.
Furman MI, Krueger LA, Barnard MR, Fox ML, Frelinger
AL, and Michelson AD. GPIIb-IIIa antagonists modulate leukocyte-platelet
aggregates in patients with ACS undergoing PCI. (Accepted
for presentation at the 75th Scientific Sessions of the
American Heart Association, Chicago, November 17- 20, 2002.)
46.
Krueger LA, Furman MI, Barnard MR, Frelinger AL,
and Michelson AD. Release of soluble CD40L from platelets
is regulated by fibrinogen binding to GPIIb-IIIa, actin
polymerization, and a matrix metalloproteinase. (Submitted
to the 44nd Annual Meeting of the American Society of Hematology,
Philadelphia, December 6 - 10, 2002.).
47.
Frelinger AL, Marchese PJ, Barnard MR, Krueger LA, Fox ML,
Furman MI, and Michelson AD. Flow cytometric assessment
of aspirin and NSAID effects on platelet function and leukocyte-platelet
aggregation. (Submitted to the 44nd Annual Meeting of the
American Society of Hematology, Philadelphia, December 6
- 10, 2002.)
48.
Frelinger AL, Mascelli MA, Jordan R, Marchese PJ, Barnard
MR, Krueger LA, Furman MI, Michelson AD. Combined
effects of GPIIb-IIIa antagonists, aspirin, apyrase and
cytoskeletal inhibitors on preformed platelet aggregates.
(Submitted to the 44nd Annual Meeting of the American Society
of Hematology, Philadelphia, December 6 - 10, 2002.)
49.
Krueger LA, Furman MI, Barnard MR, Frelinger AL,
and Michelson AD. Augmentation of platelet activation in
the presence of GPIIb-IIIa antagonists can result from antibody-mediated
FcgRIIa receptor activation. (Submitted to the 44nd Annual
Meeting of the American Society of Hematology, Philadelphia,
December 6 - 10, 2002.)
